




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/35, 31/70, A23L 1/22, 2/56</b>		A1	(11) International Publication Number: <b>WO 99/21549</b>
			(43) International Publication Date: 6 May 1999 (06.05.99)
(21) International Application Number: PCT/KR98/00324			
(22) International Filing Date: 20 October 1998 (20.10.98)			
(30) Priority Data:			
1997/55578	28 October 1997 (28.10.97)	KR	
1998/10888	28 March 1998 (28.03.98)	KR	
1998/12411	8 April 1998 (08.04.98)	KR	
1998/13283	14 April 1998 (14.04.98)	KR	
(71) Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY [KR/KR]; #39-1, Hawolkog-dong, Seongbuk-gu, Seoul 136-130 (KR).			
(72) Inventors: BOK, Song, Hae; Garam Apt. 15-1202, Samcheon-dong, Seo-gu, Daejeon 302-222 (KR). JEONG, Tae, Sook; Hanbit Apt. 127-1103, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). CHOI, Myung, Sook; Garden Heights Apt. 102-203, Bumeo-4-dong, Suseong-gu, Daegu 706-014 (KR). MOON, Surk, Sik; Gomnaru Apt. 101-601, #5, Shinkwan-dong, Gongju-shi, Chungcheongnam-do 314-110 (KR). KWON, Yong, Kook; Hanbit Apt. 126-1307, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). LEE, Eun, Sook; #49-2, Dae-hung-3-dong, Jung-gu, Daejeon 301-013 (KR). HYUN, Byung, Hwa; Hanbit Apt. 131-1401, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). CHOI, Yang, Kyu; Hanbit Apt. 137-706, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). LEE, Chul, Ho; Gyungseong Kunmaeul Apt. 120-1307, Galma-dong, Seo-gu, Daejeon 302-171 (KR). BAE, Ki, Hwan; #113-12, Goijeong-dong, Seo-gu, Daejeon 302-200 (KR). PARK, Yong, Bok; Garden Heights Apt. 102-203, Bumeo-4-dong, Suseong-gu, Daegu 706-014 (KR). LEE, Jun, Sung; Nuri Apt. 107-102, Wolpyung-dong, Seo-gu, Daejeon 302-280 (KR). SON, Kwang, Hee; Hanbit Apt. 103-1702, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). KWON, Byoung, Mog; Doryong Villa 102, #380-51, Doryong-dong, Daejeon 305-340 (KR). KIM, Young, Kook; Hanbit Apt. 102-601, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). CHOI, Doil; Kist Apt. 2-305, Doryong-dong, Yuseong-gu, Daejeon 305-340 (KR). KIM, Sung, Uk; Hanbit Apt. 110-405, #99, Oeun-dong, Yuseong-gu, Daejeon 305-333 (KR). HWANG, Ingyu; Kist Apt. 2-206, Doryong-dong, Yuseong-gu, Daejeon 305-340 (KR). AHN, Jung, Ah; #162-40, Gayang-2-dong, Dong-gu, Daejeon 300-092 (KR). PARK, Young, Bae; Hyundai Apt. 83-206, Apgujeong-dong, Kangnam-gu, Seoul 135-110 (KR). KIM, Hyo, Soo; Hyundai Apt. 85-1401, Apgujeong-dong, Kangnam-gu, Seoul 135-110 (KR). CHOE, Seong, Choon; Mapo Samsung Apt. 105-1204, Dohwa-dong, Mapo-gu, Seoul 121-040 (KR).			
		(74) Agents: JANG, Seong, Ku et al.; Dongwon Building, 3rd floor, # 275, Yangjae-Dong, Seocho-ku, Seoul 137-130 (KR).	
		(81) Designated States: CA, CN, JP, RU, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
		Published With international search report.	
(54) Title: HESPERIDIN AND HESPERETIN AS INHIBITOR OF ACYL COA-CHOLESTEROL-O-ACYLTRANSFERASE, INHIBITOR OF MACROPHAGE-LIPID COMPLEX ACCUMULATION ON THE ARTERIAL WALL AND PREVENTIVE OR TREATING AGENT FOR HEPATIC DISEASES			
			
(57) Abstract			
<p>The present invention relates to uses of hesperidin or hesperetin for inhibiting the activity of acyl CoA-cholesterol-o-acyltransferase, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and preventing or treating hepatic diseases in a mammal.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

HESPERIDIN AND HESPERETIN AS INHIBITOR OF ACYL COA-  
CHOLESTEROL-O-ACYLTRANSFERASE, INHIBITOR OF MACROPHAGE-  
LIPID COMPLEX ACCUMULATION ON THE ARTERIAL WALL AND  
PREVENTIVE OR TREATING AGENT FOR HEPATIC DISEASES

5

FIELD OF THE INVENTION

The present invention relates to uses of hesperidin or  
hesperetin for inhibiting the activity of acyl CoA-  
10 cholesterol-o-acyltransferase (ACAT), inhibiting the  
accumulation of macrophage-lipid complex on the arterial  
endothelium, and preventing or treating hepatic diseases in  
a mammal.

15 BACKGROUND OF THE INVENTION

In recent years, coronary cardio-circulatory diseases,  
e.g., atherosclerosis and hypercholesterolemia, have  
increasingly become a major cause of deaths. It has been  
20 reported that an elevated plasma cholesterol level causes  
the deposition of fat, macrophages and foam cells on the  
wall of blood vessels, such deposit leading to plaque  
formation and then to atherosclerosis(Ross, R., Nature, 362,  
801-809(1993)). One of the methods for decreasing the  
25 plasma cholesterol level is alimentotherapy to reduce the  
ingestion of cholesterol and lipids. Another method is to  
inhibit the absorption of cholesterol by inhibiting enzymes  
involved therein.

Acyl CoA-cholesterol-o-acyltransferase(ACAT) promotes  
30 the esterification of cholesterol in blood. Foam cells are  
formed by the action of ACAT and contain a large amount of  
cholesterol ester carried by low density lipoproteins. The  
formation of foam cells on the wall of artery increases with  
the ACAT activity, and, accordingly, an inhibitor of ACAT  
35 may also be an agent for preventing atherosclerosis.  
Further, it has been reported that the blood level of LDL-  
cholesterol can be reduced by inhibiting the ACAT

- 2 -

activity(Witiak, D. T. and D. R. Feller(eds.), Anti-Lipidemic Drugs: Medicinal, Chemical and Biochemical Aspects, Elsevier, pp159-195(1991)).

On the other hand, deterioration of hepatic functions may occur due to an excessive intake of alcohol or foods having a high lipid content, or an infection of hepatitis B or C virus, and it may develop into hepatitis, hepatocirrhosis or hepatic cancer. In particular, the excessive intake of fat-containing foods and alcohol causes fatty liver wherein a large amount of lipids is deposited in the liver tissue and the levels of serum GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) and  $\gamma$ -GTP( $\gamma$ -glutamyl transpeptidase) are elevated(T. Banciu et al., Med. Interne., 20, 69-71(1982); and A. Par et al., Acta. Med. Acad. Sci. Hung., 33, 309-319(1976)).

Numerous efforts have been made to develop medicines which inhibit ACAT activity; and, as a result, several compounds isolated from the cultures of various microorganisms have been reported. Examples of such compounds include pyripyropenes isolated from the culture of Aspergillus fumigatus(S. Omura et al., J. Antibiotics, 46, 1168-1169(1993)) and Acaterin isolated from Pseudomonas sp.(S. Nagamura et al., J. Antibiotics, 45, 1216-1221(1992)).

Further, as a treating agent for hypercholesterolemia, a HMG-CoA reductase inhibitor named Lovastatin® has been developed and marketed by Merck Co., U.S.A. However, this medicine is known to induce adverse side effect of increasing creatin kinase in the liver.

Accordingly, there has continued to exist a need to develop non-toxic inhibitors of ACAT and macrophage-lipid complex accumulation on the arterial epithelium, and a preventive or treating agent for the hepatic diseases.

The present inventors have endeavored to develop a novel and potent ACAT inhibitor, macrophage-lipid complex accumulation inhibitor and treating agent for the hepatic

- 3 -

diseases from natural materials; and, as a result, have discovered that hesperidin or hesperetin has a potent ACAT inhibitory activity, macrophage-lipid complex accumulation inhibitory activity, and preventive or treating activity on the hepatic diseases.

Hesperidin( $C_{28}H_{34}O_{15}$ , M.W.: 610.55) and the aglycon of hesperidin, hesperetin( $C_{16}H_{14}O_6$ , M.W.: 302.27), are flavonoids found in lemons, grapefruits, tangerines, citrons and oranges(Citrus sinensis)(Horowitz, Gentili, Tetrahedron, 19, 773(1943)).

It has been reported that hesperidin or hesperetin has capillary-enhancing, permeability-reducing, anti-platelet aggregation, anti-inflammation, anti-viral, and blood-pressure and cholesterol lowering activities(Meyer, O. C., Angiology, 45, 579-584(1994); Struckmann, J. R., et al., Angiol., 45, 419-428(1994); Matsubara, Y., et al., Japan Organic Synthesis Chem. Association Journal, 52, 318-327(1994. Mar.); Galati, E. M., et al., Farmaco., 51(3), 219-221(1996, Mar.); Monforte, M. T., et al., Farmaco., 50(9), 595-599(1995, Sep.); JP 95-86929; JP 95-86930; Chung, M. I., et al., Chin. Pharm. J.(Taipei), 46, 429-437(1994, Nov.); Galati, E. M., et al., Farmaco., 40(11), 709-712(1994, Nov.); and Emim, J. A., et al., J. Pharm. Pharmacol., 46(2), 118-122(1994)).

Further, Hesperidin has been used for the prevention and treatment of cerebral anemia, retinal hemorrhage and pelioma.

However, hitherto, none of the ACAT inhibitory activity, macrophage-lipid complex accumulation inhibitory activity and preventive or treating activity on the hepatic diseases of hesperidin or hesperetin has been reported.

#### SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a novel use of hesperidin or hesperetin for inhibiting the ACAT activity in a mammal.

- 4 -

Another object of the present invention is to provide a novel use of hesperidin or hesperetin for inhibiting the accumulation of macrophage-lipid complex on the endothelial wall of an artery in a mammal.

- 5 A further object of the present invention is to provide a novel use of hesperidin or hesperetin for preventing or treating hepatic diseases in a mammal.

#### BRIEF DESCRIPTION OF THE DRAWINGS

10

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, in which:

- 15 Figs. 1A, 1B and 1C show the arteries of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.1% hesperidin, respectively; and

- 20 Figs. 2A, 2B and 2C present the microscopic features of the livers of the rabbits administered with 1% cholesterol; 1% cholesterol plus 1 mg/kg Lovastatin®; and 1% cholesterol plus 0.1% hesperidin, respectively.

#### DETAILED DESCRIPTION OF THE INVENTION

25

In accordance with one aspect of the present invention, there is provided a use of hesperidin or hesperetin for inhibiting the acyl-CoA cholesterol-o-acyltransferase (ACAT) activity in a mammal.

- 30 In accordance with another aspect of the present invention, there is provided a use of hesperidin or hesperetin for inhibiting the accumulation of macrophage-lipid complex on the endothelial wall of an artery in a mammal.

- 35 In accordance with a further aspect of the present invention, there is provided a use of hesperidin or hesperetin for preventing or treating hepatic diseases in a

- 5 -

mammal.

Hesperidin and hesperetin may be extracted from the peel of citrus or synthesized according to the process described by Zemplen, Bogнар, Ber., 75, 1043(1943) and Seka, 5 Prosche, Monatsh., 69, 284(1936). Further, hesperetin can be prepared by the hydrolysis of hesperidin.

Hesperidin or hesperetin exerts an inhibitory effect on the ACAT activity and the accumulation of macrophage-lipid complex on the endothelial wall of an artery, and a 10 preventive or treating effect on hepatic diseases at a dose of 0.1 mg/kg/day or more, the inhibitory effect increasing with the dose thereof.

Moreover, in spite of its potent efficacies, hesperidin or hesperetin shows little toxicity or mitogenicity in tests 15 using mice. More specifically, hesperidin or hesperetin exhibits no toxicity when it is orally administered to a mouse at a dose of 100 mg/kg, which corresponds to an oral administration dose of 3 to 10 g/kg body weight of hesperidin or hesperetin for a person weighing 50 kg. 20 Further, hesperidin and hesperetin exert no adverse effects on the liver function.

The present invention also provides a pharmaceutical composition for inhibiting the ACAT activity and accumulation of macrophage-lipid complex on the endothelial 25 wall of an artery, and for preventing or treating hepatic diseases, which comprise hesperidin or hesperetin as an active ingredient and pharmaceutically acceptable excipients, carriers or diluents.

A pharmaceutical formulation may be prepared in 30 accordance with any of the conventional procedures. In preparing the formulation, the active ingredient is preferably admixed or diluted with a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet or other container. When the carrier serves as a 35 diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient. Thus, the formulations may be in the form of a

- 6 -

tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like.

5        Examples of suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, 10 methylhydroxybenzoates, propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like. The compositions 15 of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.

      The pharmaceutical composition of the present invention 20 can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction. In case of human, a typical daily dose of hesperidin or hesperetin may range from about 0.1 to 100 mg/kg body weight, preferably 3 to 10 mg/kg body weight, and 25 can be administered in a single dose or in divided doses.

      However, it should be understood that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the condition to be treated, the chosen route of 30 administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom; and, therefore, the above dose should not be intended to limit the scope of the invention in any way.

      Moreover, hesperidin or hesperetin can be incorporated 35 in foods or beverages, as an additive or a dietary supplement, for the purpose of inhibiting the ACAT activity, inhibiting the accumulation of macrophage-lipid complex on



- 7 -

the arterial endothelium and/or preventing or treating hepatic diseases. The foods or beverages may include meats; juices such as a vegetable juice(e.g., carrot juice and tomato juice) and a fruit juice(e.g., orange juice, grape juice, pineapple juice, apple juice and banana juice); chocolates; snacks; confectionery; pizza; foods made from cereal flour such as breads, cakes, crackers, cookies, biscuits, noodles and the likes; gums; dairy products such as milk, cheese, yogurt and ice creams; soups; broths; pastes, ketchups and sauces; teas; alcoholic beverages; carbonated beverages such as Coca-Cola® and Pepsi-Cola®; vitamin complexes; and various health foods.

In this case, the content of hesperidin or hesperetin in a food or beverage may range from 0.01 to 5% by weight. In particular, the beverage according to the present invention may comprise 200 to 10,000 mg of hesperidin or hesperetin per 1000 ml of the beverage.

As described above, hesperidin or hesperetin can be used as an effective, non-toxic pharmaceutical agent for inhibiting ACAT activity, inhibiting the accumulation of macrophage-lipid complex on the arterial endothelium, and/or preventing or treating hepatic diseases.

The following Examples are intended to further illustrate the present invention without limiting its scope.

Further, percentages given below for solid in solid mixture, liquid in liquid, and solid in liquid are on a wt/wt, vol/vol and wt/vol basis, respectively, and all the reactions were carried out at room temperature, unless specifically indicated otherwise.

30

Example 1: Extraction of Hesperidin from Citrus Peel

The peels of tangerines(Cheju Island, Korea), citrons(Jeollanamdo, Korea), and oranges, grapefruits and lemons(California, CA, U.S.A.) were dried at a room temperature and powdered to a particle size ranging from 100 to 200  $\mu$ m. 50 ml of methanol was added to 500 mg each of

- 8 -

the citrus peel powder and extracted in a water bath at 50°C for 6 hours. The extract thus obtained was cooled and filtered, and then methanol was added to the filtrate to a volume of 50 ml.

5 To confirm the content of hesperidin in the extract obtained above, 5.0 µl of the resulting extract was subjected to high performance liquid chromatography(HPLC) using Lichrosorb RP-8 column(5 µm, 4 x 250 mm) which was pre-equilibrated with 37 % methanol and maintained at a  
10 temperature of 30°C. The extract was eluted with 37 % methanol at a flow rate of 1.0 ml/min. Standard solutions were prepared by dissolving hesperidin(Sigma Chemical Co. U.S.A.) in methanol to final concentrations of 0.1, 0.2, 0.3, 0.4 and 0.5 mg/ml, and subjected to HPLC under the same  
15 condition as above. The eluates were detected at 280 nm with UV-VIS spectrophotometer and the content of hesperidin was calculated by comparing the areas of HPLC profiles of the citrus peel extract and the standard solution. The content(%) of hesperidin in various citrus peel extracts is  
20 shown in Table I.

Table I

	Hesperidin(%)
Orange	2.10
25 Lemon	1.40
Tangerine	2.10
grapefruit	-
citron	0.80

30

Example 2: Toxicity of Orally Administered Hesperidin or Hesperetin

35 7 to 8 week-old, specific pathogen-free ICR female mice(6 heads) each weighing about 25 to 29 g and male mice(6

- 9 -

heads) each weighing about 34 to 38 g were bred under a condition of temperature  $22\pm1^{\circ}\text{C}$ , moisture  $55\pm5\%$  and photoperiod 12L/12D. Fodder(Cheiljedang Co., mouse and rat fodder) and water were sterilized and fed to the mice.

5        Hesperidin or hesperetin was dissolved in 0.5 % Tween 80 to a concentration of 100 mg/ml, and the solution was orally administered to the mice in an amount of 0.2 ml per 20 g of mouse body weight. The solution was administered once and the mice were observed for 10 days for signs of  
10        adverse effects or death according to the following schedule: 1, 4, 8, and 12 hours after the administration and, every 12 hours thereafter. The weight changes of the mice were recorded every day to examine the effect of hesperidin or hesperetin. Further, on the 10th day, the  
15        mice were sacrificed and the internal organs were visually examined.

      All the mice were alive at day 10 and hesperidin or hesperetin showed no toxicity at a dose of 1,000 mg/kg. The autopsy revealed that the mice did not develop any  
20        pathological abnormality, and no weight loss was observed during the 10 day test period. Accordingly, it was concluded that hesperidin or hesperetin is not toxic when orally administered to an animal.

25        Example 3: Administration of Hesperidin or Hesperetin to an Animal

      30 four-week-old Sprague-Dawley rats(Taihan laboratory animal center, Korea) each weighing about 90 to 110 g were  
30        evenly divided into three dietary groups by a randomized block design. The rats of the three groups were fed with three different high-cholesterol diets, i.e., AIN-76 laboratory animal diet(ICN Biochemicals, Cleveland, OH, U.S.A.) containing 1 % cholesterol(Control group), and 1 %  
35        cholesterol plus 0.1% hesperidin or hesperetin, respectively. The compositions of diets fed to the three groups are shown in Table II.

- 10 -

Table II

	Dietary group	Control group	Hesperidin group	Hesperetin group
5	Ingredient			
	Casein	20	20	20
	D,L-methionine	0.3	0.3	0.3
	Corn starch	15	15	15
	Sucrose	49	48.9	48.9
10	Cellulose powder*	5	5	5
	Mineral mixture*	3.5	3.5	3.5
	Vitamin mixture*	1	1	1
	Choline bitartrate	0.2	0.2	0.2
	Corn oil	5	5	5
15	Cholesterol	1	1	1
	Hesperidin		0.1	-
	Hesperetin	-	-	0.1
	Total	100	100	100

20 \* Purchased from TEKLAD premier Co.(Madison, WI, U.S.A.)

The rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the three groups in terms of the feed ingestion amount and the weight gain.

30

Example 4: Determination of Total Cholesterol, HDL-Cholesterol and Neutral Lipid Content in Plasma

The effect of administering hesperidin or hesperetin to rats on the plasma cholesterol and neutral lipid content was determined as follows.

Blood samples were taken from the rats of the three

- 11 -

dietary groups and plasma HDL fractions were separated  
 therefrom by using HDL-cholesterol reagent(Sigma Chemical  
 Co., Cat. No. 352-3) containing dextran-sulfate. Total  
 cholesterol and HDL-cholesterol levels were determined by  
 5 using Sigma Diagnostic Kit Cat. No. 352-100(Sigma Chemical  
 Co., U.S.A.)(Allain et al., Clin. Chem., 20, 470-475(1974)).  
 Neutral lipid level was determined by using Sigma Diagnostic  
 Kit Cat. No. 339-50(Bucolo, G. and David, H., Clin. Chem.,  
19, 476-482(1973)). The result is shown in Table III,  
 10 wherein the total plasma cholesterol levels in hesperidin  
 and hesperetin-fed rat groups decreased by 11 % and 15%,  
 respectively, as compared with that of the control group.

Table III

15

Group Lipid Conc.	Control group	Hesperidin group	Hesperetin group
Total-C (mg/dl)	147.8±34.8	131.6±29.7	125.1±15.6
HDL-C (mg/dl)	22.2	18.7	25.7
20 $\frac{\text{HDL-C}}{\text{Total-C}}$ (%)	15.7±5.3	15±4.9	20±5.6
TG (mg/dl)	99.2±18.9	92.7±20.5	114.6±18.8

25 \* Total-C: Total-cholesterol  
 \* HDL-C: HDL-cholesterol  
 \* TG: Triglyceride

30 Example 5: Activity of Hesperidin and Hesperetin in ACAT  
 Inhibition

(Step 1) Preparation of microsomes

35 To determine the effects of hesperidin and hesperetin  
 feeding to rats on the activity of ACAT, microsomes were  
 separated from the liver tissue to be used as an enzyme  
 source.

First, the rats of the three groups prepared in Example

- 12 -

3 were sacrificed by decapitation and the livers were excised. 1 g each of the livers was homogenized in 5 ml of homogenization medium (0.1 M  $\text{KH}_2\text{PO}_4$ , pH 7.4, 0.1 mM EDTA and 10 mM  $\beta$ -mercaptoethanol). The homogenate was centrifuged at 5 3,000xg for 10 min. at 4°C and the supernatant thus obtained was centrifuged at 15,000xg for 15 min. at 4°C to obtain a supernatant. The supernatant was put into an ultracentrifuge tube (Beckman) and centrifuged at 100,000xg for 1 hour at 4°C to obtain microsomal pellets, which were 10 then suspended in 3 ml of the homogenization medium and centrifuged at 100,000xg for 1 hour at 4°C. The pellets thus obtained were suspended in 1 ml of the homogenization medium. The concentration of proteins in the resulting suspension was determined by Lowry's method and then 15 adjusted to 4 to 8 mg/ml. The resulting suspension was stored in a deep freezer (Biofreezer, Forma Scientific Inc.).

(Step 2) ACAT assay

20 6.67  $\mu\text{l}$  of 1 mg/ml cholesterol solution in acetone was mixed with 6  $\mu\text{l}$  of 10 % Triton WR-1339 (Sigma Co.) in acetone and, then, acetone was removed from the mixture by evaporation using nitrogen gas. Distilled water was added to the resulting mixture in an amount to adjust the 25 concentration of cholesterol to 30 mg/ml.

To 10  $\mu\text{l}$  of the resulting aqueous cholesterol solution were added 10  $\mu\text{l}$  of 1 M  $\text{KH}_2\text{PO}_4$  (pH 7.4), 5  $\mu\text{l}$  of 0.6 mM bovine serum albumin (BSA), 10  $\mu\text{l}$  of microsome solution obtained in (Step 1) and 55  $\mu\text{l}$  of distilled water (total 90  $\mu\text{l}$ ). The 30 mixture was pre-incubated in a waterbath at 37°C for 30 min.

10  $\mu\text{l}$  of ( $1\text{-}^{14}\text{C}$ ) oleoyl-CoA solution (0.05  $\mu\text{Ci}$ , final concentration: 10  $\mu\text{M}$ ) was added to the pre-incubated mixture and the resulting mixture was incubated in a waterbath at 37°C for 30 min. To the mixture were added 500  $\mu\text{l}$  of 35 isopropanol:heptane mixture (4:1 (v/v)), 300  $\mu\text{l}$  of heptane and 200  $\mu\text{l}$  of 0.1 M  $\text{KH}_2\text{PO}_4$  (pH 7.4), and the mixture was mixed violently by using a vortex and then allowed to stand at a

- 13 -

room temperature for 2 min.

200  $\mu$ l of the resulting supernatant was put in a scintillation bottle and 4 ml of scintillation fluid(Lumac) was added thereto. The mixture was assayed for radioactivity with 1450 Microbeta liquid scintillation counter(Wallacoy, Finland). ACAT activity was calculated as picomoles of cholesteryl oleate synthesized per min. per mg protein(pmoles/min/mg protein). The result is shown in Table IV.

10

Table IV

Group	ACAT activity (pmole/min/mg protein)	%Inhibition on ACAT activity
Control group	806.2 $\pm$ 105.2	0
0.1% hesperidin group	851.2 $\pm$ 86.0	19.2
0.1% hesperetin group	616.4 $\pm$ 60.5	23.5

20

As can be seen from Table IV, ACAT activities observed in hesperidin and hesperetin-fed rat groups are lower than that of the control group by 19.2% and 23.5%, respectively.

25 Example 6: Inhibition of Plaque Formation Caused by  
Macrophage-Lipid Complex in Hesperidin and  
Hesperetin-Fed Animals

(Step 1) Administration of hesperidin and hesperetin to  
30 animals

24 three-month-old New Zealand White rabbits(Yeonam Horticulture and Animal Husbandry College, Korea) each weighing about 2.5 to 2.6 kg were bred under a condition of temperature 20 $\pm$ 2°C, relative humidity 55 $\pm$ 5 %, and photoperiod 12L/12D. The rabbits were divided by a group of  
35

- 14 -

6 rabbits, and the rats of four groups were fed with four different diets, i.e., RC4 diet(Oriental Yeast Co., Japan) containing 1 % cholesterol(Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Merck, U.S.A.)(Comparative group);  
5 1 % cholesterol plus 0.1 % hesperidin; and 1 % cholesterol plus 0.1 % hesperetin, respectively. RC4 diet comprises 7.6 % moisture, 22.8 % crude protein, 2.8 % crude fat, 8.8 % crude ash, 14.4 % crude cellulose and 43.6 % soluble nitrogen-free substances. The rabbits were bred for 6 weeks  
10 while being allowed free access to the diets and water.

(Step 2) Analysis for fatty streak in the main artery

The rabbits bred in (Step 1) were sacrificed and their  
15 chest were incised. The main artery was cut out therefrom in a length of about 5 cm downward from the site 1 cm above the aortic valve and the fat surrounding the main artery was removed. The main artery was incised in the middle along the longitudinal axis and pinned to a dish. The moist  
20 artery was photographed and, then, staining of fatty streak was carried out in accordance with the method of Esper, E., et al.(J. Lab. Clin. Med., 121, 103-110(1993)) as follows.

A part of the incised main artery was washed three times by 2 min. with anhydrous propylene glycol and stained  
25 for 30 min. with a saturated solution of Oil Red O(ORO, Sigma Co.) dissolved in propylene glycol. Thereafter, the artery was washed twice by 3 min. with 85 % propylene glycol to remove remaining staining solution and, then washed with physical saline. The artery was photographed and the  
30 photograph was traced. The area of stained region(fatty streak region) was determined with an image analyzer(LEICA, Q-600, Germany) and its proportion(%) to the total arterial area was calculated.

On the other hand, the other part of the main artery  
35 was stained in accordance with hematoxylin-eosin(H&E) and Masson's trichrome staining methods and observed under a microscope to confirm whether the macrophage-lipid complexes



- 15 -

were accumulated in the intima, internus, elastic lamina and media.

Further, blood samples were taken from the rabbits and total cholesterol and triglyceride levels were determined in accordance with the same procedure in Example 4.

The result is shown in Table V.

Table V

10	Dietary Group	Total cholesterol (mg/dl)	Triglyceride (mg/dl)	M-L* complex area (%)
	Control group	1143	56	35
	1mg/kg Lovastatin® group	1210	66	5
15	0.1% hesperidin group	1130	40	13.5
	0.1% hesperetin group	1150	41	13

20 \* M-L complex: Macrophage-lipid complex

As can be seen from Table V, the area of macrophage-lipid complex accumulated on the arterial endothelium decreased significantly in the 1 mg/kg Lovastatin® and 0.1 % hesperidin, 0.1 % hesperetin groups, as compared to the control group. Accordingly, it has been confirmed that hesperidin and hesperetin inhibit the accumulation of macrophage-lipid complex on the arterial endothelium. In particular, it is remarkable that the inhibitory activity of hesperidin and hesperetin on the accumulation of macrophage-lipid complex was exhibited under the blood cholesterol levels above 1,100 mg/dl, which are much higher than that of normal rabbit, i.e., about 50 mg/dl. This result suggests that there may be a novel mechanism for preventing the onset of atherosclerosis, which is different from the blocking of cholesterol synthesis by a HMG-CoA reductase inhibitor, blocking of cholesterol absorption by an ACAT inhibitor, or

- 16 -

blocking of cholesterol transfer by a CETP inhibitor.

Figs. 1A, 1B and 1C show the arteries of the rabbits administered with 1 % cholesterol(control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(comparative group); and 1 % cholesterol plus 0.1 % hesperidin, respectively. As shown in Figs. 1A, 1B and 1C, a thick layer of macrophage-lipid complex was observed on the arterial endothelium of the rabbit administered with 1 % cholesterol, while no or very thin layers of macrophage-lipid complex were observed on the arterial endotheliums of the rabbits administered with 1 % cholesterol plus 1 mg/kg Lovastatin®, and 1 % cholesterol plus 0.1 % hesperidin, respectively.

Accordingly, it has been concluded that hesperidin and hesperetin strongly inhibit the accumulation of macrophage-lipid complex on the arterial endothelium.

#### Example 7: Prevention of Hepatic Diseases by Hesperidin

(Step 1) Administration of hesperidin to rats

20

20 four-week-old Sprague-Dawley rats(Taihan laboratory animal center, Korea) each weighing about 90 to 110 g were evenly divided into two dietary groups by a randomized block design. The rats of the two groups were fed with two different high-cholesterol diets, i.e., AIN-76 laboratory animal diet(ICN Biochemicals, Cleveland, OH, U.S.A.) containing 1 % cholesterol(Control group), and 1 % cholesterol plus 0.04% hesperidin, respectively. The compositions of the diets fed to the two groups are shown in Table VI.

- 17 -

Table VI

	Dietary group	Control group	Hesperidin group
	Ingredients		
5	Casein	20	20
	D,L-methionine	0.3	0.3
	Corn starch	15	15
	Sucrose	39	38.96
	Cellulose powder*	5	5
10	Mineral mixture*	3.5	3.5
	Vitamin mixture*	1	1
	Choline bitartrate	0.2	0.2
	Fat	15	15
	Cholesterol	1	1
15	Hesperidin	-	0.04
	Total	100	100

\* Purchased from TEKLAD premier Co.(Madison, WI, U.S.A.)

20

The rats were allowed to feed freely on the specified diet together with water for six weeks, the ingestion amount was recorded daily and the rats were weighed every 7 days, and then the record was analyzed. All rats showed a normal growth rate and there was observed no significant difference among the two groups in terms of the feed ingestion amount and the weight gain.

25

(Step 2) Determination of serum GOT and GPT levels

30

The effect of administering hesperidin to rats on the function of the liver was examined as follows.

Blood samples were taken from the rats of the two dietary groups and serum GOT(glutamate-oxaloacetate transaminase) and GPT(glutamate-pyruvate transaminase) levels were determined in accordance with the method of Reitman and Frankel(Reitman, S. and J. S. Frankel, Am. J.

35

- 18 -

Clin. Pathol., 28, 56(1956)). GOT and GPT are synthesized in the liver and heart, and released into blood stream upon the damage of these organs. Accordingly, GOT and GPT are representative markers of the liver-function and high serum  
5 GOT and GPT levels mean severe damage of the liver.

The result showed that GOT and GPT levels of hesperidin group were lower than those of the control group by about 30 % and 10 %, respectively.

10 (Step 3) Experiment using rabbits

The same procedure as in (Step 1) was repeated except that 30 three-month old New Zealand White rabbits(Yeonam Horticulture and Animal Husbandry College, Korea) each  
15 weighing about 2.5 to 2.6 kg were used in place of the rats, and the rabbits were fed for six weeks with three different diets, i.e., RC4 diet containing 1 % cholesterol(Control group); 1 % cholesterol plus 1 mg/kg Lovastatin®(Comparative group); and 1 % cholesterol plus 0.1 % hesperidin,  
20 respectively.

Thereafter, the livers were separated from the rabbits and the histopathological observations were carried out as follows.

The rabbits were anesthetized with an intramuscular  
25 injection of ketamine(75 mg/kg) and subjected to an abdominal incision. The color and degree of sclerosis of the liver were observed with eyes, and the liver separated from the rabbit was fixed in 10 % neutral buffered formalin for more than 24 hours. The fixed liver was washed  
30 sufficiently with water, dehydrated stepwise with 70 %, 80 %, 90 % and 100 % ethanol and, then, embedded in paraffin. The embedded liver was sectioned in 4  $\mu$ m thickness with a microtome and stained with hematoxylin and eosin. The stained liver specimen was made transparent with xylene,  
35 mounted with permount, and then observed under a microscope to confirm the presence of lesions.

Figs. 2A, 2B and 2C present the microscopic features of

- 19 -

the livers of the rabbits administered with 1 % cholesterol(control group), 1 % cholesterol plus 1 mg/kg Lovastatin®(comparative group), and 1 % cholesterol plus 0.1 % hesperidin, respectively. As shown in Figs. 2A and 2B, the hepatic cells of the control group and the comparative group are irregularly arranged and enlarged and a large amount of fat is deposited therein. In contrast, as shown in Fig. 2C, the hepatic cells of hesperidin group are normal and the deposition of fat is not observed. This result shows that hesperidin strongly inhibit the occurrence of fatty liver without toxic adverse effect to the hepatic cells.

(Step 4) Experiment using human

15

Hesperidin was orally administered to a 55-year-old man at a daily dose of 10 mg/kg for 68 days and serum GOT, GPT and  $\gamma$ GTP levels were determined just before the administration(day 0), and 45 and 68 days after the administration(day 45 and day 68), respectively. Consequently, serum GOT levels at day 45 and day 68 decreased by 17 %, respectively, in comparison to that of day 0. Serum GPT levels at day 45 and day 68 decreased by 15 % and 19 %, respectively, in comparison to that of day 0. Further, serum  $\gamma$ GTP levels at day 45 and day 68 decreased by 25 % and 51 %, respectively, in comparison to that of day 0. Surprisingly, reduction of serum  $\gamma$ GTP level at day 68 was more than 50 %, and this result suggests that hesperidin or hesperetin has a strong liver-protective activity and preventive activity on the hepatic diseases such as hepatitis, fatty liver and alcoholic fatty liver.

On the other hand, hesperidin was orally administered to a 56-year-old man, who had drunk alcoholic beverages habitually in an amount of 100 cc per day, at a daily dose of 6 mg/kg for 30 days and serum  $\gamma$ GTP level was determined just before the administration(day 0) and 30 days after the administration(day 30). Consequently, initial serum  $\gamma$ GTP

- 20 -

level at day 0 was 129 IU/l, while that of day 30 decreased to 69 IU/l which is within the normal range. This result demonstrates that hesperidin or hesperetin has a high activity of preventing alcoholic fatty liver and  
5 hepatocirrhosis.

Example 9: Foods containing Hesperidin or hesperetin

Foods containing hesperidin or hesperetin were prepared  
10 as follows.

(1) Preparation of tomato ketchup and sauce

Hesperidin or hesperetin was added to a tomato ketchup or sauce in an amount ranging from 0.01 to 5 wt% to obtain  
15 a health-improving tomato ketchup or sauce.

(2) Preparation of wheat flour foods

Hesperidin or hesperetin was added to a wheat flour in an amount ranging from 0.01 to 5 wt% and breads, cakes,  
20 cookies, crackers and noodles were prepared by using the mixture to obtain health-improving foods.

(3) Preparation of soups and gravies

Hesperidin or hesperetin was added to soups and gravies  
25 in an amount ranging from 0.01 to 5 wt% to obtain health-improving soups and gravies.

(4) Preparation of ground beef

Hesperidin or hesperetin was added to ground beef in an  
30 amount ranging from 0.01 to 5 wt% to obtain a health-improving ground beef.

(5) Preparation of dairy product

Hesperidin or hesperetin was added to milk in an amount  
35 ranging from 0.01 to 5 wt% and various dairy products such as butter and ice cream were prepared by using the milk.

However, in case of cheese preparation, hesperidin or

- 21 -

hesperetin was added to the coagulated milk protein; and, in case of yogurt preparation, hesperidin or hesperetin was added to the coagulated milk protein obtained after the fermentation.

5

Example 10: Beverages containing Hesperidin or hesperetin

(1) Preparation of vegetable juice

200 to 10,000 mg of hesperidin or hesperetin was added  
10 to 1000 ml of a tomato or carrot Juice to obtain a health-improving vegetable juice.

(2) Preparation of fruit juice

200 to 10,000 mg of hesperidin or hesperetin was added  
15 to 1000 ml of an apple or grape Juice to obtain a health-improving fruit juice.

(3) Preparation of carbonated drink

200 to 10,000 mg of hesperidin or hesperetin was added  
20 to 1000 ml of Coca-Cola® or Pepsi-Cola® to obtain a health-improving carbonated drink.

While the invention has been described with respect to the above specific embodiments, it should be recognized that  
25 various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

- 22 -

What is claimed is:

1. A use of hesperidin or hesperetin for inhibiting  
the activity of acyl CoA-cholesterol-o-acyltransferase (ACAT)  
5 in a mammal.

2. The use of claim 1, wherein the mammal is human.

3. The use of claim 1, wherein hesperidin or  
10 hesperetin is administered to the mammal in the form of a  
composition containing same, said composition being selected  
from the group consisting of: a pharmaceutical composition,  
a food composition and a beverage composition.

15 4. The use of claim 3, wherein the effective amount  
of hesperidin or hesperetin contained in the pharmaceutical  
composition ranges from 0.1 to 100 mg/kg body weight/day.

5. The use of claim 3, wherein the content of  
20 hesperidin or hesperetin in the food composition ranges from  
0.01 to 5% by weight.

6. The use of claim 3, wherein the food is meats,  
chocolates, snacks, confectionery, pizza, foods made from  
25 cereal flour, gums, dairy products, soups, broths, pastes,  
ketchups, sauces, vitamin complexes or health foods.

7. The use of claim 6, wherein the foods made from  
cereal flour is breads, cakes, crackers, cookies, biscuits  
30 or noodles.

8. The use of claim 3, wherein the beverage  
composition is dairy products, vegetable juices, fruit  
juices, teas, alcoholic beverages or carbonated beverages.  
35

9. The use of claim 3, wherein the content of  
hesperidin or hesperetin in the beverage composition ranges



- 23 -

from 200 to 10,000 mg per 1,000 ml of the beverage.

10. A use of hesperidin or hesperetin for inhibiting the accumulation of macrophage-lipid complex on the arterial  
5 endothelium in a mammal.

11. The use of claim 10, wherein the mammal is human.

12. The use of claim 10, wherein hesperidin or  
10 hesperetin is administered to the mammal in the form of a composition containing same, said composition being selected from the group consisting of: a pharmaceutical composition, a food composition and a beverage composition.

13. The use of claim 12, wherein the effective amount  
15 of hesperidin or hesperetin contained in the pharmaceutical composition ranges from 0.1 to 100 mg/kg body weight/day.

14. The use of claim 12, wherein the content of  
20 hesperidin or hesperetin in the food composition ranges from 0.01 to 5% by weight.

15. The use of claim 12, wherein the food composition  
is meats, chocolates, snacks, confectionery, pizza, foods  
25 made from cereal flour, gums, dairy products, soups, broths, pastes, ketchups, sauces, vitamin complexes or health foods.

16. The use of claim 15, wherein the foods made from  
cereal flour is breads, cakes, crackers, cookies, biscuits  
30 or noodles.

17. The use of claim 12, wherein the beverage  
composition is dairy products, vegetable juices, fruit  
juices, teas, alcoholic beverages or carbonated beverages.  
35

18. The use of claim 12, wherein the content of  
hesperidin or hesperetin in the beverage composition ranges

- 24 -

from 200 to 10,000 mg per 1,000 ml of the beverage.

19. A use of hesperidin or hesperetin for preventing or treating a hepatic disease in a mammal.

5

20. The use of claim 19, wherein the mammal is human.

21. The use of claim 19, wherein hesperidin or hesperetin is administered to the mammal in the form of a composition being selected from the group consisting of: a  
10 pharmaceutical composition, a food composition and a beverage composition.

22. The use of claim 21, wherein the effective amount  
15 of hesperidin or hesperetin contained in the pharmaceutical composition ranges from 0.1 to 100 mg/kg body weight/day.

23. The use of claim 21, wherein the content of hesperidin or hesperetin in the food composition ranges from  
20 0.01 to 5% by weight.

24. The use of claim 21, wherein the food composition is meats, chocolates, snacks, confectionery, pizza, foods made from cereal flour, gums, dairy products, soups, broths,  
25 pastes, ketchups, sauces, vitamin complexes or health foods.


25. The use of claim 24, wherein the foods made from cereal flour is breads, cakes, crackers, cookies, biscuits or noodles.

30

26. The use of claim 21, wherein the beverage composition is dairy products, vegetable juices, fruit juices, teas, alcoholic beverages or carbonated beverages.

35 27. The use of claim 21, wherein the content of hesperidin or hesperetin in the beverage composition ranges from 200 to 10,000 mg per 1,000 ml of the beverage.


1/6  
Fig. 1A



BEST AVAILABLE COPY


2/6

Fig. 1B




BEST AVAILABLE COPY

3/6  
Fig. 1C




BEST AVAILABLE COPY

4/6  
Fig. 2A




REST AVAILABLE COPY

5/6  
Fig. 2B



BEST AVAILABLE COPY

6/6  
Fig. 2C





# INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 98/00324

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC <sup>6</sup> : A 61 K 31/35,31/70; A 23 L 1/22,2/56 According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC <sup>6</sup> : A 61 K; A 23 L Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) QUESTEL: WPIL				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	Database WPIL on Questel, week 9702, London: Derwent Publications Ltd., AN 97-017298, Class A61K, JP 08-283154 A (NIPPON SHINYAKU CO., LTD.) 29 October 1996 (29.10.96), abstract.	1-27		
X	Database WPIL on Questel, week 9702, London: Derwent Publications Ltd., AN 97-014823, Class A61K, JP 08-280358 A (NIPPON SHINYAKU CO., LTD.) 29 October 1996 (29.10.96), abstract.	1-27		
X	Database WPIL on Questel, week 9001, London: Derwent Publications Ltd., AN 90-001242, Class A61B, EP 0 347 864 A (STRYDOM A.J.C.) 27 December 1989 (27.12.89), abstract.	10-18		
A	WO 94/23 717 A1 (THE PROCTER & GAMBLE COMPANY) 27 October 1994 (27.10.94), abstract; claims 1,2,7,8; page 5, line 13 - page 6, line 7; examples 1,2,3.	1-27		
A	Database WPIL on Questel, week 9631, London: Derwent Publications Ltd., AN 96-302114, Class A61K, EP 0 719 554 A1 (KUREHA CHEM. IND. CO., LTD.)	1-27		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; border: none;">           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier application or patent but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 50%; vertical-align: top; border: none;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 17 December 1998 (17.12.98)		Date of mailing of the international search report 28 January 1999 (28.01.99)		
Name and mailing address of the ISA/ Austrian Patent Office Kohlmarkt 8-10; A-1014 Vienna Facsimile No. 1/53424/535		Authorized officer Mazzucco Telephone No. 1/53424/437		

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 98/00324

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	03 July 1996 (03.07.96), abstract. Database WPIL on Questel, week 9506, London: Derwent Publications Ltd., AN 95-038283, Class A61K, EP 0.633 022 A2 (KUREHA CHEM. IND. CO., LTD.) 11 January 1995 (11.01.95), abstract.	1-27
A	Database WPIL on Questel, week 9248, London: Derwent Publications Ltd., AN 92-395348, Class A61K, JP 04-295428 A (DAIICHI PHARM. CO., LTD.) 20 October 1992 (20.10.92), abstract.	1-27
A	Database WPIL on Questel, week 8926, London: Derwent Publications Ltd., AN 89-192550, Class A61K, WO 89/05 141 A (TSUMURA & CO.) 15 June 1989 (15.06.89), abstract.	1-27
A	Database WPIL on Questel, week 8003, London: Derwent Publications Ltd., AN 80-04477C, Class A23G, JP 54-154569 A (LOTTE KK.) 05 December 1979 (05.12.79), abstract. -----	1-27

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/KR 98/00324

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-27

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 1-27 are directed to a method of treatment of the human or animal body by therapy (Rule 39.1 (iv) PCT) the search has been carried out and based on the alleged effects.

2. ☐ Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.  
PCT/KR 98/00324

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WD A1 9423717	27-10-94	AU A1 66665/94	08-11-94
		AU A1 81907/98	22-10-98
		CA AA 2159985	27-10-94
		CN A 1123523	29-05-96
		EP A1 695181	07-02-96
		IL A0 109334	31-07-94
		JP T2 8509224	01-10-96
		ZA A 9402717	16-01-95
		US A 5587176	24-12-96